Analytical Data
-
Gene name
ELAVL3
- Application
-
Alternative Names
Hu-antigen C ;HuCParaneoplastic cerebellar degeneration-associated antigen;Paraneoplastic limbic encephalitis antigen 21
-
Species
Human
-
Source
Yeast
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q14576
-
Expression Region
1-367aa
-
Molecular Weight
41.5 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ELAVL3, also known as HuC, is a member of the ELAV-like protein family, which is known for its role in RNA binding and post-transcriptional regulation. This protein is primarily expressed in the nervous system and plays a crucial role in neuronal differentiation, development, and maintenance. Given its involvement in RNA metabolism, ELAVL3 is implicated in various cellular processes, including mRNA stability, localization, and translation. Aberrant expression or mutations of ELAVL3 have been associated with several neurological disorders, including Alzheimer's disease and various forms of cancer. Researchers are increasingly interested in the recombinant expression of ELAVL3 to better understand its functional mechanisms and interactions in neuronal environments. By producing a purified form of this protein, scientists aim to study its binding affinities, RNA target specificity, and how it influences gene expression patterns in neuronal cells. Furthermore, examining the structural attributes of ELAVL3 through recombinant methodologies can provide insights into its RNA recognition motifs and offer potential therapeutic strategies for diseases linked to its dysregulation. Understanding ELAVL3's role in RNA biology may pave the way for novel interventions in neurodegenerative diseases and could also shed light on its potential as a biomarker for certain malignancies.
